AU3681095A - Method and pharmaceutical composition for prevention and treatment of brain damage - Google Patents

Method and pharmaceutical composition for prevention and treatment of brain damage

Info

Publication number
AU3681095A
AU3681095A AU36810/95A AU3681095A AU3681095A AU 3681095 A AU3681095 A AU 3681095A AU 36810/95 A AU36810/95 A AU 36810/95A AU 3681095 A AU3681095 A AU 3681095A AU 3681095 A AU3681095 A AU 3681095A
Authority
AU
Australia
Prior art keywords
prevention
treatment
pharmaceutical composition
brain damage
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36810/95A
Inventor
Akira Arimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of AU3681095A publication Critical patent/AU3681095A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU36810/95A 1994-09-22 1995-09-21 Method and pharmaceutical composition for prevention and treatment of brain damage Abandoned AU3681095A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1994/010752 WO1996009318A1 (en) 1994-09-22 1994-09-22 Method and pharmaceutical composition for prevention and treatment of brain damage
WOUS9410752 1994-09-22
PCT/US1995/012057 WO1996009064A1 (en) 1994-09-22 1995-09-21 Method and pharmaceutical composition for prevention and treatment of brain damage

Publications (1)

Publication Number Publication Date
AU3681095A true AU3681095A (en) 1996-04-09

Family

ID=22243017

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36810/95A Abandoned AU3681095A (en) 1994-09-22 1995-09-21 Method and pharmaceutical composition for prevention and treatment of brain damage

Country Status (3)

Country Link
JP (1) JPH10505863A (en)
AU (1) AU3681095A (en)
WO (2) WO1996009318A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017533A (en) * 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US6165755A (en) * 1997-01-23 2000-12-26 University Of Victoria Innovation And Development Corporation Chicken neuropeptide gene useful for improved poultry production
ES2335827T3 (en) * 1998-07-20 2010-04-05 Ipsen Pharma PACAP PEPTIDAL ANALOGS.
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
EP1423509A2 (en) 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
JP4906231B2 (en) 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド Prolactin-induced increase in neural stem cell number and its therapeutic use
EP1507551A2 (en) * 2002-05-03 2005-02-23 Neuronova AB The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells
AU2003250705A1 (en) * 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
EP1740202B1 (en) 2004-02-13 2012-05-09 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
WO2005102375A1 (en) * 2004-04-23 2005-11-03 Senju Pharmaceutical Co., Ltd. Corneal neuritogenesis promoter containing pacap and its derivative
EP1778268B1 (en) 2004-07-21 2016-05-04 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
CA2664629A1 (en) 2005-09-27 2007-04-05 Christopher Gregg Oligodendrocyte precursor cell proliferation regulated by prolactin
EP2004211A4 (en) 2006-03-17 2010-07-07 Stem Cell Therapeutics Corp Dosing regimes for lh or hcg and epo for treatment of neurological disorders
WO2009046876A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009043519A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2197467A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
AU2010313122A1 (en) * 2009-11-02 2012-05-24 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
ITMI20110583A1 (en) 2011-04-08 2012-10-09 Hmfra Hungary Ltd Liability Company OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) FOR THE PURPOSE OF RESTORING THE NORMAL VISUAL FUNCTION IN THE GLAUCOMA EARLY
JPWO2019098254A1 (en) * 2017-11-14 2020-12-03 千寿製薬株式会社 PACAP Stabilizing Peptide
WO2020230869A1 (en) * 2019-05-14 2020-11-19 千寿製薬株式会社 Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
EP0768090A3 (en) * 1990-07-18 1997-06-18 Takeda Chemical Industries Ltd Polypeptides having c-AMP producing activity for the prevention of neuronal cell death
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
JPH06228002A (en) * 1993-01-29 1994-08-16 Takeda Chem Ind Ltd Secretgranin ii production promoter containing pacap

Also Published As

Publication number Publication date
JPH10505863A (en) 1998-06-09
WO1996009318A1 (en) 1996-03-28
WO1996009064A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
AU3681095A (en) Method and pharmaceutical composition for prevention and treatment of brain damage
AU2277595A (en) Device and method for treatment of skin
AU2103195A (en) Device and method for treatment of dentition
AU4995693A (en) Apparatus and method for the treatment of blood
AU1436595A (en) Method of treatment of traumatic brain injury
AU1976695A (en) Method and apparatus for treatment of atrial fibrillation
AU2187992A (en) Composition and method for disease treatment
AU5439996A (en) Compositions and methods for treating pain
AU2296995A (en) Composition and method for treatment of cmv infection
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
EP1014972A4 (en) Method of treatment and pharmaceutical composion
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
PL309600A1 (en) Pharmaceutical compositions for preventing and treating neoplastic diseases and method of obtaining them
AUPO359396A0 (en) A method of treatment and pharmaceutical compositions useful for same
AU3768795A (en) Method and compositions for hair treatment
HUP9501807A2 (en) Method for treatment of asbestcement products
AU8369998A (en) Medicinal product and method for treatment and prevention of cognitive disorders
ZA9510108B (en) Composition and method for prevention and treatment of HIV-1 infection
AU3607597A (en) Pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
AU2750297A (en) Methods for prevention and/or treatment of neutropenia
AU2992295A (en) Therapeutic method and compounds of use therein
AU4521497A (en) Method and apparatus for the treatment of organic matter
AU6979594A (en) Compositions and methods for treatment and prevention of retinal dysfunctions
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers